Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Research & Development (2016 - 2025)

Agios Pharmaceuticals' Research & Development history spans 14 years, with the latest figure at $88.1 million for Q4 2025.

  • For Q4 2025, Research & Development rose 6.33% year-over-year to $88.1 million; the TTM value through Dec 2025 reached $339.5 million, up 12.7%, while the annual FY2025 figure was $339.5 million, 12.7% up from the prior year.
  • Research & Development reached $88.1 million in Q4 2025 per AGIO's latest filing, up from $86.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $91.9 million in Q2 2025 to a low of $57.7 million in Q1 2021.
  • Average Research & Development over 5 years is $73.7 million, with a median of $72.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: increased 25.98% in 2023, then decreased 11.47% in 2024.
  • A 5-year view of Research & Development shows it stood at $73.3 million in 2021, then decreased by 4.09% to $70.3 million in 2022, then increased by 10.23% to $77.5 million in 2023, then rose by 6.87% to $82.8 million in 2024, then increased by 6.33% to $88.1 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Research & Development are $88.1 million (Q4 2025), $86.8 million (Q3 2025), and $91.9 million (Q2 2025).